0001628280-24-027351.txt : 20240607
0001628280-24-027351.hdr.sgml : 20240607
20240607182935
ACCESSION NUMBER: 0001628280-24-027351
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Laura A
CENTRAL INDEX KEY: 0001869194
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36485
FILM NUMBER: 241031047
MAIL ADDRESS:
STREET 1: 116 HUNTINGTON AVENUE, 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARDELYX, INC.
CENTRAL INDEX KEY: 0001437402
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
BUSINESS PHONE: 510-745-7047
MAIL ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER COMPANY:
FORMER CONFORMED NAME: NTERYX INC
DATE OF NAME CHANGE: 20080611
4
1
wk-form4_1717799368.xml
FORM 4
X0508
4
2024-06-05
0
0001437402
ARDELYX, INC.
ARDX
0001869194
Williams Laura A
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210
WALTHAM
MA
02451
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-06-05
4
M
0
100000
2.75
A
467152
D
Common Stock
2024-06-05
4
S
0
45000
7.124
D
422152
D
Common Stock
2024-06-05
4
S
0
100000
7.125
D
322152
D
Stock Option (Right to Buy)
2.75
2024-06-05
4
M
0
100000
0
D
2033-01-05
Common Stock
100000
251000
D
This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams
2024-06-07